nach oben

Erschienen in:

14.05.2016 | Original Article

Hepatitis C virus and its protein NS4B activate the cancer-related STAT3 pathway via the endoplasmic reticulum overload response

verfasst von: Lingbao Kong, Shanshan Li, Xilan Yu, Xiaonan Fang, Ahui Xu, Mingjie Huang, Xiaoyu Wu, Yunli Guo, Fenglin Guo, Jin Xu

Erschienen in: Archives of Virology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Oxidative stress induces the activation of signal transducer and activator of transcription 3 (STAT3), which plays an important role in hepatocellular carcinoma (HCC). We have previously reported that hepatitis C virus (HCV) and its protein NS4B induce the production of reactive oxygen species (ROS) via the endoplasmic reticulum overload response (EOR) in human hepatocytes. Here, we found that NS4B and HCV induce STAT3 activation and stimulate the expression of cancer-related STAT3 target genes, including VEGF, c-myc, MMP-9 and Mcl-1, by EOR in human hepatocytes. Moreover, the cancer-related STAT3 pathway activated by NS4B and HCV via EOR were found to promote human hepatocyte viability. Taken together, these findings revealed that HCV NS4B might contribute to HCC by activating the EOR-mediated cancer-related STAT3 pathway, and this could provide novel insights into HCV-induced HCC.

Nur mit Berechtigung zugänglich

Bromberg J (2002) Stat proteins and oncogenesis. J Clin Investig 109(9):1139–1142. doi:10.1172/JCI15617 CrossRefPubMedPubMedCentral

Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809. doi:10.1038/nrc2734 CrossRefPubMedPubMedCentral

Waris G, Turkson J, Hassanein T, Siddiqui A (2005) Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol 79(3):1569–1580. doi:10.1128/JVI.79.3.1569-1580.2005 CrossRefPubMedPubMedCentral

Atkinson GP, Nozell SE, Benveniste ET (2010) NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 10(4):575–586. doi:10.1586/ern.10.21 CrossRefPubMed

Lindenbach BD, Rice CM (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436(7053):933–938. doi:10.1038/nature04077 CrossRefPubMed

Ding Q, Cao X, Lu J, Huang B, Liu YJ, Kato N, Shu HB, Zhong J (2013) Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J Hepatol 59(1):52–58. doi:10.1016/j.jhep.2013.03.019 CrossRefPubMed

Li S, Yu X, Guo Y, Kong L (2012) Interaction networks of hepatitis C virus NS4B: implications for antiviral therapy. Cell Microbiol 14(7):994–1002. doi:10.1111/j.1462-5822.2012.01773.x CrossRefPubMed

Mathew S, Ali A, Abdel-Hafiz H, Fatima K, Suhail M, Archunan G, Begum N, Jahangir S, Ilyas M, Chaudhary AG, Al Qahtani M, Mohamad Bazarah S, Qadri I (2014) Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis 26:327–339. doi:10.1016/j.meegid.2014.06.014 CrossRef

Li Y, Zhang Q, Liu Y, Luo Z, Kang L, Qu J, Liu W, Xia X, Liu Y, Wu K, Wu J (2012) Hepatitis C virus activates Bcl-2 and MMP-2 expression through multiple cellular signaling pathways. J Virol 86(23):12531–12543. doi:10.1128/JVI.01136-12 CrossRefPubMedPubMedCentral

10.

Zhou JJ, Chen RF, Deng XG, Zhou Y, Ye X, Yu M, Tang J, He XY, Cheng D, Zeng B, Zhou QB, Li ZH (2014) Hepatitis C virus core protein regulates NANOG expression via the stat3 pathway. FEBS Lett 588(4):566–573. doi:10.1016/j.febslet.2013.11.041 CrossRefPubMed

11.

Li S, Kong L, Yu X (2015) The expanding roles of endoplasmic reticulum stress in virus replication and pathogenesis. Crit Rev Microbiol 41(2):150–164. doi:10.3109/1040841X.2013.813899 CrossRefPubMed

12.

Kong L, Li S, Huang M, Xiong Y, Zhang Q, Ye L, Liu J, Zhu X, Sun R, Guo Y (2015) The roles of endoplasmic reticulum overload response induced by HCV and NS4B protein in human hepatocyte viability and virus replication. PLoS One 10(4):e0123190. doi:10.1371/journal.pone.0123190 CrossRefPubMedPubMedCentral

13.

Li S, Ye L, Yu X, Xu B, Li K, Zhu X, Liu H, Wu X, Kong L (2009) Hepatitis C virus NS4B induces unfolded protein response and endoplasmic reticulum overload response-dependent NF-kappaB activation. Virology 391(2):257–264. doi:10.1016/j.virol.2009.06.039 CrossRefPubMed

14.

Kong LB, Ye LB, Ye L, Timani KA, Zheng Y, Liao QJ, Li BZ, Gao B (2006) Establishment of stable HeLa cell lines expressing enzymatically active hepatitis C virus RNA polymerase. Arch Virol 151(2):361–367. doi:10.1007/s00705-005-0656-0 CrossRefPubMed

15.

Kong L, Li S, Liao Q, Zhang Y, Sun R, Zhu X, Zhang Q, Wang J, Wu X, Fang X, Zhu Y (2013) Oleanolic acid and ursolic acid: novel hepatitis C virus antivirals that inhibit NS5B activity. Antivir Res 98(1):44–53. doi:10.1016/j.antiviral.2013.02.003 CrossRefPubMed

16.

Kong L, Li S, Han X, Xiang Z, Fang X, Li B, Wang W, Zhong H, Gao J, Ye L (2007) Inhibition of HCV RNA-dependent RNA polymerase activity by aqueous extract from Fructus Ligustri Lucidi. Virus Res 128(1–2):9–17. doi:10.1016/j.virusres.2007.03.020 CrossRefPubMed

17.

Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102(26):9294–9299. doi:10.1073/pnas.0503596102 CrossRefPubMedPubMedCentral

18.

Arii S, Mise M, Harada T, Furutani M, Ishigami S, Niwano M, Mizumoto M, Fukumoto M, Imamura M (1996) Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24(2):316–322. doi:10.1053/jhep.1996.v24.pm0008690399 CrossRefPubMed

19.

Peng S, Wang Y, Peng H, Chen D, Shen S, Peng B, Chen M, Lencioni R, Kuang M (2014) Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. Hepatology 60(4):1264–1277. doi:10.1002/hep.27236 CrossRefPubMed

20.

Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, Bodingbauer M, Crevenna R, Monia BP, Peck-Radosavljevic M, Wacheck V (2006) Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol 44(1):151–157. doi:10.1016/j.jhep.2005.09.010 CrossRefPubMed

21.

Wang L, Zhang X, Jia LT, Hu SJ, Zhao J, Yang JD, Wen WH, Wang Z, Wang T, Zhao J, Wang RA, Meng YL, Nie YZ, Dou KF, Chen SY, Yao LB, Fan DM, Zhang R, Yang AG (2014) c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology 59(5):1850–1863. doi:10.1002/hep.26720 CrossRefPubMed

22.

Watanabe J, Kushihata F, Honda K, Sugita A, Tateishi N, Mominoki K, Matsuda S, Kobayashi N (2004) Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 135(6):604–612. doi:10.1016/j.surg.2003.11.015 CrossRefPubMed

23.

McCartney EM, Helbig KJ, Narayana SK, Eyre NS, Aloia AL, Beard MR (2013) Signal transducer and activator of transcription 3 is a proviral host factor for hepatitis C virus. Hepatology 58(5):1558–1568. doi:10.1002/hep.26496 CrossRefPubMed

24.

Toker A, Cantley LC (1997) Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387(6634):673–676. doi:10.1038/42648 CrossRefPubMed

25.

Wheeler DL, Li Y, Verma AK (2005) Protein kinase C epsilon signals ultraviolet light-induced cutaneous damage and development of squamous cell carcinoma possibly through Induction of specific cytokines in a paracrine mechanism. Photochem Photobiol 81(1):9–18. doi:10.1562/2004-08-12-RA-271 CrossRefPubMed

26.

Tardif KD, Waris G, Siddiqui A (2005) Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol 13(4):159–163. doi:10.1016/j.tim.2005.02.004 CrossRefPubMed

Titel: Hepatitis C virus and its protein NS4B activate the cancer-related STAT3 pathway via the endoplasmic reticulum overload response
verfasst von: Lingbao Kong
Shanshan Li
Xilan Yu
Xiaonan Fang
Ahui Xu
Mingjie Huang
Xiaoyu Wu
Yunli Guo
Fenglin Guo
Jin Xu
Publikationsdatum: 14.05.2016
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 8/2016
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-016-2892-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hepatitis C virus and its protein NS4B activate the cancer-related STAT3 pathway via the endoplasmic reticulum overload response

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

Evaluation of a smartphone-based rapid fluorescent diagnostic system for H9N2 virus in specific-pathogen-free chickens

Identification of antigenic domains in the non-structural protein of Muscovy duck parvovirus

Beet western yellows virus infects the carnivorous plant Nepenthes mirabilis

Genetic relatedness of infectious hematopoietic necrosis virus (IHNV) from cultured salmonids in Korea

Prevalence and molecular characterization of human noroviruses and sapoviruses in Ethiopia

Genomic characterization of influenza A (H7N9) viruses isolated in Shenzhen, Southern China, during the second epidemic wave

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin